Racial differences in longitudinal toxicities of anticancer agents in early phase cancer clinical trials.
Junki MizusawaHioryuki SatoLarry V RubinsteinTakeo FujiwaraKan YonemoriAkihiro HirakawaPublished in: Cancer medicine (2023)
Although we identified several racial differences in longitudinal toxicities, most were of generally lower grade. Further study is needed to clarify the cause of racial differences in treatment-associated toxicities.